Originally presented as a satellite symposium at the 2025 HFSA Annual Scientific Meeting in Minneapolis, this educational activity is targeted to cardiologists, neurologists, heart failure specialists, and the interprofessional team of nurse practitioners and cardiac nurses that help manage patients with transthyretin-mediated amyloidosis (ATTR). Designed as both a data intensive and a case-based practicum, this session will offer learners an expert-led appraisal of the evolving clinical trial evidence and regulatory updates for novel therapeutics in ATTR, with an emphasis on clinical best practices for treatment selection and sequencing in ATTR-CM, ATTR-PN, and ATTR of mixed phenotype, and will include an intensive review of established and emerging pharmacologic mechanisms and incisively examine how they interface with ATTR pathophysiology.

CME-Pod listeners will also get a unique “glimpse beyond the cutting edge of the calculus” in a segment led by the two winners of the 1st Annual (2024) ATTR Early-Career Research Forum, in which they detail the rationale, design, results, and real-world promise of their original ATTR research projects. Finally, the session will be punctuated by an interactive and dynamic case-based discussion that equips and engages cardiologists, neurologists, and other members of the ATTR multidisciplinary and interprofessional treatment team to bridge the disconnect between clinician and patient expectations, with the overarching strategic goal of harmonizing shared decision-making, optimizing evidence-based treatment decisions, and improving outcomes across the ATTR disease continuum.

To obtain CE credit for listening, complete the activity pre-test here: https://form.jotform.com/AcademyCME/24C15Pre

After the session, complete the post-test, activity evaluation, and CE credit request here: https://form.jotform.com/AcademyCME/24C15post

Thank you for listening to CME-Pod! We at Cornerstone hope it equips you to improve your clinical practice and better serve your patients.

To take the post-test and claim your CE credit for this session, please visit: https://online.epocrates.com/contextuallink/cme/activity/OQUMHW

This educational initiative is targeted to the community-based multidisciplinary and interprofessional HHT treatment team of primary care physicians, internists, hematologists, oncologists, gastroenterologists, otorhinolaryngologists, allergists, and nurses/nurse practitioners, pharmacists, and physician assistants. Strategically developed to promote community clinician awareness of HHT and galvanize optimization of HHT-associated ID and IDA management, this episode will begin with an overview of HHT epidemiology and pathophysiology, emphasizing diverse disease manifestations and clinical presentation, then move into an appraisal of current guideline recommendations for diagnosing, screening, and treating HHT-associated IDA, with an incisive focus on the role of intravenous (IV) iron as iron replacement therapy. Practical differentiators between currently-available IV iron products, inclusive of total dose infusion (TDI) capacity and relative risk for IV iron-induced hypophosphatemia, will be highlighted and emphasized throughout the activity using practical patient case scenarios.

In this episode of CME-Pod, leading clinical experts - Drs. Truman Milling, Jr, Deborah Siegal, and Geoffrey Barnes - will provide learners with a circumscription of the clinical benefits and risks associated with DOAC usage, inclusive of patient-specific, disease-specific, and drug-specific risk factors, and will examine the unique pharmacologic mechanisms of established and emerging specific reversal therapeutics. A review of the evidentiary base will follow, encompassing completed, ongoing, and planned clinical trials for specific reversal agents, as well as recent readouts and pending regulatory updates that have the potential to meaningfully shift the calculus. The session will conclude with a case-based segment that tangibly highlights the imperative need for multidisciplinary collaboration and the importance of individualized, data-driven treatment selection.

To access the webinar on Healio, complete the post-test and activity evaluation, and claim your CE credit, please follow this link: https://cme.healio.com/cardiology/20240112/optimizing-outcomes-for-patients-with-doac-related-bleeding